Published in Clin Cancer Res on January 12, 2010
Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol (2011) 3.20
Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol (2010) 2.71
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res (2012) 2.24
Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res (2011) 2.15
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell (2011) 2.04
Cancer stem cells in glioblastoma. Genes Dev (2015) 1.91
Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res (2013) 1.86
Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS One (2011) 1.50
miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res (2013) 1.46
Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A (2013) 1.33
Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res (2012) 1.29
Genetic analysis of cytomegalovirus in malignant gliomas. J Virol (2012) 1.19
Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells. Am J Pathol (2011) 1.18
Hypoxia potentiates glioma-mediated immunosuppression. PLoS One (2011) 1.17
PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol (2015) 1.16
Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol (2012) 1.16
The controversial role of microglia in malignant gliomas. Clin Dev Immunol (2013) 1.11
Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol (2010) 1.10
Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function. PLoS One (2011) 1.07
The zinc finger transcription factor ZFX is required for maintaining the tumorigenic potential of glioblastoma stem cells. Stem Cells (2014) 1.05
Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ (2011) 1.04
Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs (2012) 1.03
Stem cells as drug delivery methods: application of stem cell secretome for regeneration. Adv Drug Deliv Rev (2014) 0.99
Paracrine effects of stem cells in wound healing and cancer progression (Review). Int J Oncol (2014) 0.99
Cancer stem cell plasticity and tumor hierarchy. World J Stem Cells (2015) 0.96
The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother (2015) 0.96
Immune therapeutic targeting of glioma cancer stem cells. Target Oncol (2010) 0.95
A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro Oncol (2013) 0.95
Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking? Lab Invest (2013) 0.92
Melanoma-initiating cells exploit M2 macrophage TGFβ and arginase pathway for survival and proliferation. Oncotarget (2014) 0.92
Immunocompetent murine models for the study of glioblastoma immunotherapy. J Transl Med (2014) 0.92
Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death. Acta Neuropathol (2011) 0.91
The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers (Basel) (2014) 0.91
Cellular immunotherapy for high-grade glioma. Immunotherapy (2011) 0.91
Adoptive cell therapies for glioblastoma. Front Oncol (2013) 0.90
Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget (2015) 0.88
Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. Immunotherapy (2014) 0.87
Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth. Oncotarget (2015) 0.86
Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nat Commun (2015) 0.85
Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas. J Exp Clin Cancer Res (2012) 0.84
The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. Neuro Oncol (2015) 0.84
Immune responses to human cancer stem-like cells/cancer-initiating cells. Cancer Sci (2015) 0.84
CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1. Clin Cancer Res (2016) 0.83
Galectins and their ligands: negative regulators of anti-tumor immunity. Glycoconj J (2012) 0.83
Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid (2012) 0.81
Vaccines targeting cancer stem cells: are they within reach? Cancer J (2011) 0.81
Genetically modified T cells to target glioblastoma. Front Oncol (2013) 0.80
Translating the combination of TGFβ blockade and radiotherapy into clinical development in glioblastoma. Oncoimmunology (2012) 0.80
Association between Prediagnostic Allergy-Related Serum Cytokines and Glioma. PLoS One (2015) 0.80
The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells. Acta Neuropathol (2014) 0.79
Therapeutic vaccination based on side population cells transduced by the granulocyte-macrophage colony-stimulating factor gene elicits potent antitumor immunity. Cancer Gene Ther (2017) 0.78
Circulating anti-filamin C autoantibody as a potential serum biomarker for low-grade gliomas. BMC Cancer (2014) 0.78
miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma. Clin Investig (Lond) (2011) 0.78
Human cytomegalovirus antigens in malignant gliomas as targets for adoptive cellular therapy. Front Oncol (2014) 0.77
Dendritic cells loaded with pancreatic Cancer Stem Cells (CSCs) lysates induce antitumor immune killing effect in vitro. PLoS One (2014) 0.77
The early antitumor immune response is necessary for tumor growth: Re-visiting Prehn's hypothesis in the human melanoma system. Oncoimmunology (2012) 0.77
Tumour-processed osteopontin and lactadherin drive the protumorigenic reprogramming of microglia and glioma progression. Oncogene (2016) 0.76
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
Do Increased Doses to Stem-Cell Niches during Radiation Therapy Improve Glioblastoma Survival? Stem Cells Int (2016) 0.76
Retraction: Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res (2015) 0.75
Mutations of the human interferon alpha-2b gene in brain tumor patients exposed to different environmental conditions. Cancer Gene Ther (2015) 0.75
Systemic T Cells Immunosuppression of Glioma Stem Cell-Derived Exosomes Is Mediated by Monocytic Myeloid-Derived Suppressor Cells. PLoS One (2017) 0.75
Effects of Malignant Melanoma Initiating Cells on T-Cell Activation. Methods Mol Biol (2016) 0.75
The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients. Hum Vaccin Immunother (2014) 0.75
Cancer stem cell hypothesis: a brief summary and two proposals. Cytotechnology (2012) 0.75
Interferon Regulatory Factor 7 Promoted Glioblastoma Progression and Stemness by Modulating IL-6 Expression in Microglia. J Cancer (2017) 0.75
DICER governs characteristics of glioma stem cells and the resulting tumors in xenograft mouse models of glioblastoma. Oncotarget (2016) 0.75
NKG2D ligand expression in pediatric brain tumors. Cancer Biol Ther (2016) 0.75
Association Between Prediagnostic Serum 25-Hydroxyvitamin D Concentration and Glioma. Nutr Cancer (2015) 0.75
Glioma Stem Cells but Not Bulk Glioma Cells Upregulate IL-6 Secretion in Microglia/Brain Macrophages via Toll-like Receptor 4 Signaling. J Neuropathol Exp Neurol (2016) 0.75
Neurotransplantation: lux et veritas, fiction or reality? J Neurosurg Sci (2011) 0.75
Crosstalk between M2 macrophages and glioma stem cells. Cell Oncol (Dordr) (2017) 0.75
Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy. PLoS One (2017) 0.75
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res (2004) 14.73
Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood (2004) 13.79
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer (2006) 8.50
Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature (2006) 7.69
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol (2008) 6.41
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 5.96
Neural stem cells and the origin of gliomas. N Engl J Med (2005) 5.43
HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol (2003) 5.35
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell (2009) 4.94
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood (2003) 4.43
T-lymphocyte entry into the central nervous system. J Neurosci Res (1991) 4.28
Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci (2005) 3.97
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood (1994) 3.74
Adult stem cells for tissue repair - a new therapeutic concept? N Engl J Med (2003) 3.15
Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A (2007) 3.09
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02
Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res (2003) 2.27
Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci (2003) 2.22
Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells. Haematologica (2003) 2.17
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res (2008) 2.15
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res (2003) 1.92
A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res (2007) 1.91
Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med (1999) 1.88
Modulation of T-cell function by gliomas. Immunol Today (1991) 1.78
Successful therapy must eradicate cancer stem cells. Stem Cells (2006) 1.78
Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells (2007) 1.53
CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent. PLoS One (2009) 1.50
Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol (2006) 1.43
Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res (2008) 1.26
Tumor antigens in astrocytic gliomas. Glia (1995) 1.09
Chemicals that modulate stem cell differentiation. Proc Natl Acad Sci U S A (2008) 0.99
Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration. Oncol Rep (2007) 0.97
Multipotent, dedifferentiated cancer stem-like cells from brain gliomas. Stem Cells Dev (2006) 0.96
Expression pattern of galectin-3 in neural tumor cell lines. J Neurosci Res (2000) 0.90
Nitric-oxide-dependent systemic immunosuppression in animals with progressively growing malignant gliomas. Cell Immunol (2000) 0.87
Differentiating therapy in acute myeloid leukemia. Leukemia (1996) 0.82
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol (2009) 9.90
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
The transcriptional network for mesenchymal transformation of brain tumours. Nature (2009) 8.44
The role of autophagy in cancer development and response to therapy. Nat Rev Cancer (2005) 8.18
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res (2005) 5.17
FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell (2011) 3.58
FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res (2006) 3.28
Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res (2005) 3.10
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res (2005) 3.07
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene (2004) 2.82
Retracted Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells. Cancer Res (2013) 2.75
Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol (2010) 2.71
Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol (2007) 2.70
Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res (2006) 2.70
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol (2006) 2.53
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev (2011) 2.48
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Altered adenosine-to-inosine RNA editing in human cancer. Genome Res (2007) 2.38
Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst (2007) 2.23
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst (2008) 2.21
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery (2012) 2.19
Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res (2011) 2.15
Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol (2012) 2.02
The incidence and management of secondary abdominoplasty and secondary abdominal contour surgery. Plast Reconstr Surg (2014) 2.02
FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res (2008) 2.01
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol (2007) 2.01
Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther (2010) 2.00
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol (2010) 1.99
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol (2012) 1.96
Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res (2006) 1.91
A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res (2007) 1.91
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst (2003) 1.86
Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. J Neurosurg (2010) 1.85
Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery (2002) 1.83
YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res (2005) 1.81
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res (2008) 1.80
Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol (2014) 1.77
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest (2013) 1.76
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother (2007) 1.70
Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res (2009) 1.69
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol (2009) 1.69
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2008) 1.69
Factors influencing the risk of local recurrence after resection of a single brain metastasis. J Neurosurg (2010) 1.68
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther (2009) 1.67
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol (2013) 1.63
Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst (2006) 1.63
The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res (2008) 1.62
Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res (2005) 1.57
Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One (2011) 1.57
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2009) 1.53
Origin of chordoid glioma of the third ventricle. Arch Pathol Lab Med (2006) 1.51
Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res (2009) 1.51
WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res (2007) 1.49
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol (2008) 1.47